#MYQORZO
LightNews LightNews
merlintrader.bsky.social
Cytokinetics ($CYTK) Stock Hub 2026: MYQORZO, Aficamten and the Hypertrophic Cardiomyopathy Franchise Expansion

https://merlintrader.com/cytokinetics-incorporated-stock-hub/
Cytokinetics ($CYTK) Stock Hub: ACACIA, MAPLE, MYQORZO
Cytokinetics ($CYTK) Stock Hub updated Aug. 29, 2026: ACACIA-HCM and MAPLE-HCM analyses, MYQORZO launch, Nov. 14 PDUFA, cash and risks.
merlintrader.com
September 18, 2026 at 10:54 AM
formdelta.bsky.social
📄 #CYTK 10-Q — what changed
MD&A now says: "In July 2026, the Medicines and Healthcare products Regulatory Agency (MHRA) granted MYQORZO marketing authorization across the United Kingdom for the treatment of symptomatic oHCM in adult patients."
📈 Full redline → https://www.formdelta.com/ticker/CYT
FormDelta — Insider Trading Alerts
What CYTOKINETICS INC changed in their own words, quarter over quarter.
www.formdelta.com
September 15, 2026 at 9:30 PM
medpagetoday.com
"Every way, shape, or form you look at this there was benefit." -- Ahmad Masri, MD, of @ohsunews.bsky.social Medical Group, discussing results from a trial of aficamten (Myqorzo) in symptomatic nonobstructive hypertrophic cardiomyopathy. #ESCCongress
www.medpagetoday.com/meetingcover...
Nonobstructive Heart Enlargement Responds to Aficamten
Trial results extend range of benefits beyond drug's current indication
www.medpagetoday.com
September 8, 2026 at 2:11 PM
pharmaphorum.bsky.social
Cytokinetics has revealed highly anticipated data from the ACACIA-HCM study of #Myqorzo in non-obstructive hypertrophic cardiomyopathy at #ESC2026.
ESC26: Cytokinetics' big data reveal for Myqorzo impresses
Cytokinetics has revealed highly anticipated data from the ACACIA-HCM study of Myqorzo in non-obstructive hypertrophic cardiomyopathy at ESC 2026
pharmaphorum.com
August 31, 2026 at 1:54 PM
medpagetoday.com
Treatment with aficamten (Myqorzo) improved exercise capacity as well as health status and symptoms in patients with symptomatic nonobstructive hypertrophic cardiomyopathy in a large, double-blind, placebo-controlled trial. #ESCCongress
https://www.medpagetoday.com/meetingcoverage/esc/122812
Nonobstructive Heart Enlargement Responds to Aficamten
Trial results extend range of benefits beyond drug's current indication
www.medpagetoday.com
August 28, 2026 at 7:36 PM
endpts.com
Cytokinetics eyes a broader Myqorzo label with new data in hand.
endpoints.news/esc26-data-i...
Data in hand, Cytokinetics looks to expanded Myqorzo approval
Cytokinetics' Myqorzo shows positive ACACIA-HCM trial data for nHCM at ESC, potentially doubling market reach; priced at $108,400 per year, competing with BMS' Camzyos.
endpoints.news
August 28, 2026 at 5:26 PM
endpts.com
Cytokinetics sues Bristol Myers over patents, escalating their rivalry.
endpoints.news/cytokinetics...
Cytokinetics brings patent suit against Bristol Myers, escalating rivalry
Cytokinetics sued Bristol Myers Squibb to invalidate a patent on Camzyos, claiming it unfairly targets its rival heart drug Myqorzo (aficamten).
endpoints.news
August 14, 2026 at 8:27 PM
marketwire.bsky.social
📰 #Finance
Cytokinetics targets >50% MYQORZO new-to-brand share by end of 2026 while planning nHCM sNDA in Q4
seekingalpha.com
August 7, 2026 at 3:24 AM
signalbloom.ai
Cytokinetics' MYQORZO Launch Annihilates Estimates, But Soaring Launch Costs Widen Losses https://signalbloom.ai/news/CYTK/cytokinetics-myqorzo-launch-annihilates-estimates-but-soaring-launch-costs-widen-losses $CYTK #Earnings via @signalbloom.ai
August 6, 2026 at 8:23 PM
endpts.com
Braveheart Bio priced an upsized $383M IPO to push a Hengrui-licensed heart drug into Phase 3, where it would compete with Bristol Myers and Cytokinetics.
Braveheart lands $383M IPO to take Hengrui cardio drug into Phase 3
Braveheart Bio prices $382.5M IPO, tapping Hengrui-licensed BHB-1893 to challenge Bristol Myers' Camzyos and Cytokinetics' Myqorzo in cardiomyopathy.
endpoints.news
August 6, 2026 at 2:31 PM
ipharmaservices.bsky.social
NHS ने ओब्सट्रक्टिव HCM के लिए अफिकाम्टेन (Myqorzo) को मंजूरी दी है। #इंग्लैंड के लगभग 6600 वयस्क रोगियों को #NHS के तहत इस एक बार दैनिक कार्डियक मायोसिन इनहिबिटर तक तेज़ी से पहुंच मिल सकती है।
www.ipharmacenter.com/post/uk-gree...
#अफिकाम्टेन #HCM #कार्डियोलॉजी #NHS #यूकेस्वास्थ्य #हृदयअपमान #फार्मा_न्यूज़
UK greenlights aficamten: thousands with obstructive HCM gain faster access to once-daily therapy
England is set to offer a new oral treatment to an estimated 6,600 adults living with obstructive hypertrophic cardiomyopathy after regulators and health economists moved in tandem to clear the drug f...
www.ipharmacenter.com
July 31, 2026 at 7:22 AM
ipharmaservices.bsky.social
NHS 가 폐색성 비대성 심근병증에 아피캄텐(Myqorzo) 을 승인했습니다. #잉글랜드의 약 6600 명 성인이 #NHS 를 통해 1 일 1 회 복용하는 심근 미오신 억제제에 더 빨리 접근할 수 있을 전망입니다.
www.ipharmacenter.com/post/uk-gree...
#아피캄텐 #HCM #심장혈관 #NHS #영국의료 #심부전 #제약뉴스
UK greenlights aficamten: thousands with obstructive HCM gain faster access to once-daily therapy
England is set to offer a new oral treatment to an estimated 6,600 adults living with obstructive hypertrophic cardiomyopathy after regulators and health economists moved in tandem to clear the drug f...
www.ipharmacenter.com
July 31, 2026 at 7:21 AM
ipharmaservices.bsky.social
O NHS aprovou o aficamten (Myqorzo) para a miocardiopatia hipertrofica obstrutiva. Cerca de 6600 adultos na #Inglaterra poderão ter acesso mais rápido a este inibidor da miosina cardíaca de toma diária através do #NHS.
www.ipharmacenter.com/post/uk-gree...
#Aficamten #HCM #Cardiologia #NHS
UK greenlights aficamten: thousands with obstructive HCM gain faster access to once-daily therapy
England is set to offer a new oral treatment to an estimated 6,600 adults living with obstructive hypertrophic cardiomyopathy after regulators and health economists moved in tandem to clear the drug f...
www.ipharmacenter.com
July 31, 2026 at 7:21 AM
ipharmaservices.bsky.social
Il NHS ha approvato aficamten (Myqorzo) per la cardiomiopatia ipertrofica ostruttiva. Circa 6600 adulti in #Inghilterra potrebbero accedere più rapidamente a questo inibitore della miosina cardiaca a somministrazione quotidiana tramite il #NHS.
www.ipharmacenter.com/post/uk-gree...
UK greenlights aficamten: thousands with obstructive HCM gain faster access to once-daily therapy
England is set to offer a new oral treatment to an estimated 6,600 adults living with obstructive hypertrophic cardiomyopathy after regulators and health economists moved in tandem to clear the drug f...
www.ipharmacenter.com
July 31, 2026 at 7:20 AM
ipharmaservices.bsky.social
El NHS ha autorizado aficamtén (Myqorzo) para la miocardiopatía hipertrófica obstructiva. Unas 6600 personas en #Inglaterra podrían acceder antes a este inhibidor de la miosina cardíaca de toma diaria.
www.ipharmacenter.com/post/uk-gree...
#Aficamtén #HCM #Cardiología #NHS #SaludReinoUnido
UK greenlights aficamten: thousands with obstructive HCM gain faster access to once-daily therapy
England is set to offer a new oral treatment to an estimated 6,600 adults living with obstructive hypertrophic cardiomyopathy after regulators and health economists moved in tandem to clear the drug f...
www.ipharmacenter.com
July 31, 2026 at 7:16 AM
ipharmaservices.bsky.social
NHS have cleared aficamten (Myqorzo) for obstructive HCM. Around 6600 adults in #England could gain faster #NHS access to the once-daily cardiac myosin inhibitor.
www.ipharmacenter.com/post/uk-gree...
#Aficamten #HCM #Cardiology #NHS #UKHealth #HeartFailure #PharmaNews
UK greenlights aficamten: thousands with obstructive HCM gain faster access to once-daily therapy
England is set to offer a new oral treatment to an estimated 6,600 adults living with obstructive hypertrophic cardiomyopathy after regulators and health economists moved in tandem to clear the drug f...
www.ipharmacenter.com
July 31, 2026 at 7:15 AM
pharmaphorum.bsky.social
#Cytokinetics is one of the first drugmakers to benefit from the #UK's dual #regulatory and #reimbursement appraisals, getting a green light for its #obstructivehypertrophic ardiomyopathy (HCM) drug #Myqorzo.
Cytokinetics' cardiomyopathy drug cleared for NHS use
Cytokinetics gets simultaneous MHRA and NICE approvals for hypertrophic cardiomyopathy (HCM) therapy Myqorzo.
buff.ly
July 30, 2026 at 2:30 PM
blueresearch.bsky.social
Cytokinetics announces MHRA authorization for Myqorzo
Reported Thursday, Jul 30 - 6:22am EDT (TheFly subscription required to read more.)
thefly.com
July 30, 2026 at 10:30 AM
handle.invalid
🚨 Cytokinetics (CYTK) Launches MYQORZO in Germany for Obstructive HCM Treatment #Macro #Economy #Markets
Buzzer Intelligence
June 15, 2026 at 7:01 AM
handle.invalid
🚨 Cytokinetics (CYTK) Launches MYQORZO in Germany for Obstructive HCM Treatment #Macro #Economy #Markets
Buzzer Intelligence
June 13, 2026 at 8:01 PM
themedicalletter.bsky.social
It's Trivia Tuesday! This question is from our article Aficamten (Myqorzo) for Obstructive Hypertrophic Cardiomyopathy https://medicalletter.org/afica755c
June 9, 2026 at 7:09 PM